Jim Hickey’s American Politics

Let's Get Real.

Seattle Genetics’ Growth under Dr. Seagall’s Leadership

Clay B. Siegall, Ph.D., is a scientist by training and also a co-founder of Seattle Genetics that was founded in 1998. He is the company’s president, CEO and also serves as the board’s chairman. He earned his Ph.D. in Genetics from George Washington University and a bachelor’s degree in Zoology for Maryland University. He has written more than 70 publications. Dr. Siegall also hold 15 patents as at present. He focuses on the cancer therapies and this has enabled Seattle Genetics to focus on drug development and intense scientific research. Between 1991 -1997, Dr. Siegall worked for Bristol –Meyers Squibb Pharmaceutical Research institute. He later moved to the National Cancer Institute and also worked at National Institute of Health for 17 years. He has served on the board of directors for two private biotechnology companies, Alder Pharmaceuticals and Mirna Therapeutics. Mirna therapeutics also focuses on the development and sale of microRNA.

The main aim of Seattle Genetics is to help patients during the treatment process through provision of effective and highly researched rugs. The company has also developed antibody-drug conjugates (ADCs) that are used in the treatment of cancer. An example of ADC developed by Seattle Genetics is Brentuximab. It employs a linker system that is stable in the bloodstream but targets the tumor cells by releasing MMAE when it is linked to tumor’s CD30. It ensures that only target cells are affected and hence maintain the healthy cells thereby reducing the effects of the chemotherapy.

Dr. Siegall has provided advanced and skilled leadership that has propelled Seattle Genetics to enter several licensed agreements that allows the widespread use of its unique and advanced ADC technology. Genetech (Roche), GlaxoSmithKline, AbbVie and Pfizer are some of the companies that Seattle Genetics have partnered with to ensure their products are sold globally. Through this strategic partnership, the company has been able to generate $300million. In 2011, Seattle Genetics received an accelerated approval from U.S Food and Drug Administration (FDA) for one of their products known as ADCETRIS. Dr. Siegall’s leadership has enabled Seattle Genetics’ capital growth. Therefore, it secured funds both through public and private financing.

Continue learning about Clay Siegall

http://seekingalpha.com/article/3969434-seattle-genetics-sgen-clay-b-siegall-q1-2016-results-earnings-call-transcript

http://executives.findthecompany.com/l/23957/Dr-Clay-B-Siegall-PhD

Comments are closed.